Text Size: a  |   a 

Teva Announces Positive Results for Study of Fremanezumab

July 10, 2017

Many suffer from chronic migraines around the globe. They can be unpredictable and crippling. Recently, Teva Pharmaceutical Industries Ltd. announced positive results from a Phase III HALO study of fremanezumab, an investigational treatment for the prevention of migraines. In the chronic migraine (CM) study, patients treated with fremanezumab experienced statistically significant reduction in the number of monthly headache days.

“Migraine is a serious, debilitating neurological condition that substantially impacts all aspects of a person’s life,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva. “Our Phase III clinical trial program has exhibited extremely encouraging results, including with a quarterly dosing regimen, for fremanezumab in chronic migraine. We are grateful to the patients and clinical investigators who participated in this study and helped to advance our understanding of the potential of fremanezumab as a preventive treatment option for the millions of people suffering from migraine.”

The Phase III HALO EM and CM studies are 16-week studies to compare the safety, tolerability, and efficacy of four dose regimens of subcutaneous fremanezumab compared to placebo in adults with episodic and chronic migraine. In the CM study, 1,130 patients were randomized to receive subcutaneous injections of fremanezumab followed by monthly 225 mg for two months or three monthly doses of matching placebo. Results showed that the drug had significantly reduced the severity of the patients with migraines, representing a potential new option to address chronic migraines.

Via TevaPharm